Drugs in Space II
Merck and Schering-Plough will conduct protein crystal growth experiments aboard the space shuttle Discovery, due for lift-off March 13. Merck will supply a sample of elastase to help determine the enzyme's structure, while Schering will grow crystals of gamma interferon. The two companies provided similar experiments for the Discovery mission last September. Merck's principal investigator is MS&D Research Labs biophysicist Manuel Navia, PhD, who was also aboard the shuttle in September. Schering's experiment will be conducted by VP-Biotechnology T.L. Nagabhushan, PhD.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."